

**MOLECULAR ASPECTS OF ANTICANCER  
DRUG–DNA INTERACTIONS**

**Volume 2**

# TOPICS IN MOLECULAR AND STRUCTURAL BIOLOGY

## **Series Editors**

Stephen Neidle  
*Institute of Cancer Research*  
*Sutton, Surrey, UK*

Watson Fuller  
*Department of Physics*  
*University of Keele, UK*

Jack S. Cohen  
*Georgetown University*  
*USA*

## **Recent titles**

Protein–Nucleic Acid Interaction  
*Edited by Wolfram Saenger and Udo Heinemann (1989)*

Calcified Tissue  
*Edited by David W. L. Hukins (1989)*

Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression  
*Edited by Jack S. Cohen (1989)*

Molecular Mechanisms in Muscular Contraction  
*Edited by John M. Squire (1990)*

Connective Tissue Matrix, Part 2  
*Edited by David W. L. Hukins (1990)*

New Techniques of Optical Microscopy and Microspectroscopy  
*Edited by Richard J. Cherry (1990)*

Molecular Dynamics: Applications in Molecular Biology  
*Edited by Julia M. Goodfellow (1990)*

Water and Biological Macromolecules  
*Edited by Eric Westhof (1993)*

Topics in Molecular and Structural Biology

**MOLECULAR ASPECTS OF  
ANTICANCER DRUG–DNA  
INTERACTIONS  
Volume 2**

*Edited by*

**Stephen Neidle**

*Institute of Cancer Research  
Sutton, Surrey, UK*

*and*

**Michael Waring**

*Dept of Pharmacology  
University of Cambridge*

**M**  
MACMILLAN

© The contributors 1994

Softcover reprint of the hardcover 1st edition 1994

All rights reserved. No reproduction, copy or transmission of this publication may be made without written permission.

No paragraph of this publication may be reproduced, copied or transmitted save with written permission or in accordance with the provisions of the Copyright, Designs and Patents Act 1988, or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 9HE.

Any person who does any unauthorised act in relation to this publication may be liable to criminal prosecution and civil claims for damages.

First published 1994 by  
THE MACMILLAN PRESS LTD  
Houndmills, Basingstoke, Hampshire RG21 2XS  
and London  
Companies and representatives  
throughout the world

ISBN 978-1-349-13332-1 ISBN 978-1-349-13330-7 (eBook)

DOI 10.1007/978-1-349-13330-7

ISSN 0265-4377

A catalogue record for this book is available  
from the British Library

# Contents

<i>The Contributors</i>	viii
<i>Preface</i>	x
<b>1 DNA topoisomerases</b> <i>R. K. Ralph, W. Judd, Y. Pommier and K. W. Kohn</i>	1
1 Introduction	1
2 Topoisomerase I (top I)	3
3 Topoisomerase II (top II)	24
4 Conclusions	66
<b>2 Cellular and molecular pharmacology of the anthrapyrazole antitumour agents</b> <i>L. H. Patterson and D. R. Newell</i>	96
1 Introduction	96
2 Rationale for development of the anthrapyrazoles	96
3 Structural requirements for anthrapyrazole antitumour activity	98
4 Cellular pharmacology of the anthrapyrazoles	110
5 Molecular pharmacology of the anthrapyrazoles	112
6 Activation of anthrapyrazoles in biological systems	117
7 Preclinical and clinical pharmacology of the anthrapyrazoles	123
8 Conclusions	123
<b>3 Calicheamicin</b> <i>G. A. Ellestad and W.-d. Ding</i>	130
1 Introduction	130
2 Isolation, structure and chemistry	131
3 Affinity of calicheamicin $\gamma_1^I$ for DNA	135
4 Plasmid DNA cleavage studies	136
5 DNA binding/cleavage specificity	137

6	Structural features important for DNA binding and discrimination	140
7	NMR evidence for solution conformation	141
8	Evidence for a hydrophobic contribution to the calicheamicin–DNA association	142
9	DNA cleavage chemistry	145
10	Mechanism of trisulfide cleavage	150
11	Biochemical basis for cytotoxicity	152
12	Summary	153
13	Addendum	161
<b>4</b>	<b>Molecular pharmacology of intercalator–groove binder hybrid molecules</b> <i>C. Bailly and J.-P. Hélichart</i>	162
1	Introduction	162
2	Isolexins, lexitropsins and combilexins	164
3	Naturally occurring multivalent molecules	167
4	Netropsin–acridine hybrid molecules	168
5	Distamycin–ellipticine hybrid molecules	178
6	Intercalator–peptide conjugates	181
7	Conclusion	186
<b>5</b>	<b>Bleomycins: Mechanism of polynucleotide recognition and oxidative degradation</b> <i>A. Natrajan and S. M. Hecht</i>	197
1	Introduction	197
2	Oxygen activation by iron bleomycin	200
3	Other metallobleomycins	209
4	Interaction of bleomycin with DNA	211
5	Nucleic acid degradation by bleomycin	224
6	Future prospects	233
<b>6</b>	<b>Kinetic analysis of drug–nucleic acid binding modes: Absolute rates and effects of salt concentration</b> <i>W. D. Wilson and F. A. Tanius</i>	243
1	Introduction	243
2	Nucleic acid binding modes	244
3	Ion effects on nucleic acid structure and interactions	246
4	Quantitative aspects	248
5	Methods	255
6	Applications to drug–nucleic acid complexes: Classical intercalation, threading intercalation and groove-binding	259
7	Association reactions	259
8	Dissociation reactions	262
9	Mechanism of nucleic acid–drug interactions	266

<b>7 Acridine-based anticancer drugs</b>	<i>W. A. Denny and B. C. Baguley</i>	270
1	Introduction	270
2	9-Anilinoacridines	271
3	Acridinecarboxamides	279
4	Nitroacridines	284
5	Polyacridines	286
6	Acridines as carriers for other functionalities	291
7	Acridine alkaloids	295
8	Acridones	296
9	Conclusions	297
<b>8 The mitomycins: Natural cross-linkers of DNA</b>	<i>M. Tomasz</i>	312
1	Introduction	312
2	Reductive activation of mitomycins to bifunctional alkylating agents	314
3	Bioreductive alkylation products of mitomycins with DNA: Isolation and structure of the MC–DNA cross-link	318
4	Mechanism of the reductive alkylation of DNA	323
5	Acidic activation of mitomycin C: Switch of regioselectivity of alkylation from N <sup>2</sup> to N-7 of guanine	326
6	Conformation of the mitomycin–DNA complex	328
7	DNA sequence specificity of the covalent reactions of mitomycin with DNA	335
8	Ternary mitomycin–DNA–protein interactions	341
9	Summary of the molecular details of mitomycin–DNA interactions: Significance for drug design	341
<i>Index</i>		351

# The Contributors

**Bruce C. Baguley**  
Cancer Research Laboratory  
University of Auckland School of  
Medicine  
Private Bag 90192  
Auckland  
New Zealand

**Christian Bailly**  
Department of Pharmacology  
University of Cambridge  
Tennis Court Road  
Cambridge CB2 1QJ  
UK

**William A. Denny**  
Cancer Research Laboratory  
Auckland Division Cancer Society of  
New Zealand Inc.  
Auckland Medical School  
University of Auckland  
Private Bag 90192  
Auckland  
New Zealand

**Wei-dong Ding**  
Infectious Disease Research Section  
Medical Research Division  
Lederle Laboratories  
American Cyanamid Company  
Pearl River  
New York 10965  
USA

**George A. Ellestad**  
Infectious Disease Research Section

Medical Research Division  
Lederle Laboratories  
American Cyanamid Company  
Pearl River  
New York 10965  
USA

**Sidney M. Hecht**  
Department of Chemistry  
University of Virginia  
Charlottesville  
Virginia 22901  
USA

**Jean-Pierre Hélichart**  
Centre de Recherche INSERM  
Place de Verdun  
59045 Lille Cedex  
France

**Warren Judd**  
School of Biological Sciences  
University of Auckland  
Private Bag 92019  
Auckland  
New Zealand

**Kurt W. Kohn**  
Laboratory of Molecular  
Pharmacology  
Development Therapeutics Program  
National Cancer Institute  
National Institutes of Health  
Building 37 Room 5C25  
Bethesda  
Maryland 20892  
USA



**Anand Natrajan**  
Department of Biology  
University of Virginia  
Charlottesville  
Virginia 22901  
USA

**David R. Newell**  
Division of Oncology  
University of Newcastle upon Tyne  
Cancer Research Unit  
The Medical School  
Framlington Place  
The University  
Newcastle-upon-Tyne NE2 4HH  
UK

**Laurence H. Patterson**  
Department of Pharmacy  
School of Applied Sciences  
De Montfort University  
The Gateway  
Leicester LE1 9BH  
UK

**Yves Pommier**  
Laboratory of Molecular  
Pharmacology  
Development Therapeutics Program  
National Cancer Institute  
Bethesda  
Maryland 20892  
USA

**Raymond K. Ralph**  
School of Biological Sciences  
University of Auckland  
Private Bag 92019  
Auckland  
New Zealand

**Fariar A. Tanious**  
Laboratory for Chemical and  
Biological Sciences  
Georgia State University  
Atlanta  
Georgia 30303  
USA

**Maria Tomasz**  
Department of Chemistry  
Hunter College  
City University of New York  
695 Park Avenue  
New York  
New York 10021  
USA

**W. David Wilson**  
Department of Chemistry  
Georgia State University  
University Plaza  
Atlanta  
Georgia 30303  
USA

## Preface

DNA has long been a key target for cancer chemotherapy. Indeed, the first agents to be employed clinically in the treatment of human cancer (the nitrogen mustards) are DNA cross-linking agents. Spectacular advances have occurred during recent years in the treatment of childhood leukaemia and testicular cancer, largely as a result of the development of better DNA-interactive agents. Even though the majority of solid tumours remain resistant to chemotherapy, there is real promise that a new, third-generation of platinum compounds will prove successful in the treatment of ovarian cancer. Clinical advances in such key areas are the ultimate objective of much current research in cancer chemotherapy and biology. Future progress must surely result from wise application of the large body of fundamental knowledge being accumulated from studies in a whole range of disciplines. No one doubts that clinical success will increasingly depend upon the exploitation of such knowledge and on the interplay between it and more applied disciplines. This is especially important as the molecular and cellular bases of malignant cell growth become better understood. So the study of drug-DNA interactions has moved on from the position of a dozen years ago, when our understanding of the molecular basis of drug action was relatively poor, as were the prospects for rational design of new drugs, to a much more positive position with new horizons.

These two volumes survey our current knowledge about the mode of action of the major classes of DNA-interactive antitumour agents, and in so doing provide pointers for the discovery of new therapeutic substances. The reader will notice that certain related topics have been grouped together; indeed in one instance (that of topoisomerase inhibitors), what were originally planned as two separate chapters by different authors have been amalgamated into one (by mutual consent!) so as to produce a more balanced and co-ordinated treatment. Elsewhere the

relationships between topics may be less obvious, but we hope that our choices will stimulate cross-fertilization of ideas.

An enterprise involving many authors such as this requires the cooperation of all the contributors if it is to succeed. We are grateful to everyone for their efforts in ensuring delivery of their manuscripts promptly and for making our task as editors such a pleasurable one. Both of us are indebted to the Cancer Research Campaign for supporting work on drug–DNA interactions in our own laboratories over a number of years. To the hard-working staff of the Campaign, as well as to those who devote their lives to the alleviation of cancer at the bedside and in the laboratory, we dedicate this pair of volumes.

*Sutton and Cambridge, 1993*

S. N.  
M. W.